US FDA approves Tegsedi to treat polyneuropathy of hereditary transthyretin─mediated amyloidosis in adults

Akcea Therapeutics, Inc, an affiliate of Ionis Pharmaceuticals, Inc, and Ionis Pharmaceuticals, Inc, announced that the US Food and Drug Administration (FDA) has approved Tegsedi (inotersen) for the treatment

More From BioPortfolio on "US FDA approves Tegsedi to treat polyneuropathy of hereditary transthyretin─mediated amyloidosis in adults"